Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection

Starting soon · Phase 1

Conditions studied: Mycobacterium Abscessus Infection, Bacteriophage Therapy, Pulmonary Disease

In brief

The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.

Key facts

Study ID

NCT07429162

Run by

Alberta Health services

People needed

1

Starts

2026-07-02

Expected to finish

2028-07-02

Last updated by the study team

2026-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Consent to participation

You may not qualify if…

• non-consent to participation

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.